<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868023</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0809-PR-0038</org_study_id>
    <secondary_id>2008-004842-10</secondary_id>
    <nct_id>NCT00868023</nct_id>
  </id_info>
  <brief_title>Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients</brief_title>
  <official_title>A Phase II, Multinational, Multicentre, Double Blind, Double Dummy, Randomised, 5-way Cross-over, Placebo and Active Controlled Clinical Study to Test the Non-inferiority of a Single Dose of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder) Via NEXT™ DPI 1 or 4 Inhalations Versus CHF 1535 (Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg) pMDI With HFA-134a Propellant 1 or 4 Puffs on FEV1 AUC0-12h in Partly Controlled Adult Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multinational, multicentre, randomised, double blind, double dummy, placebo and active
      controlled, 5-way cross over
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the non-inferiority in terms of FEV1 AUC0-12h between a single dose of CHF
      1535 via NEXT DPI and CHF 1535 via HFA-134a &quot;extrafine&quot; pMDI in partly controlled adult
      asthmatic patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12h</measure>
    <time_frame>Every week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVC as assessed at the same time points as for FEV1; Peak FEV1 in terms of absolute values and % of change from baseline Safety evaluation</measure>
    <time_frame>Every week</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 DPI : BDP/Formo 400/24 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF 1535 pMDI HFA : BDP/Formo 400/24 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 DPI : BDP/Formo 100/6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF 1535 pMDI HFA : BDP/Formo 100/6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 Next DPI</intervention_name>
    <description>CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster BDP/Formoterol</intervention_name>
    <description>BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 Next DPI</intervention_name>
    <description>CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster BDP/Formoterol</intervention_name>
    <description>BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's written informed consent obtained prior to any study-related procedures.

          -  Outpatient male or female aged ≥ 18 years.

          -  Evidence for &quot;partly controlled&quot; asthma in the 2 weeks before the screening visit

          -  Under previous inhaled corticosteroids (ICS) treatment at the screening visit

          -  Forced expiratory volume in the first second (FEV1) ≥ 60% and ≤ 90% of the predicted
             normal values at the screening visit.

          -  A documented positive response to the reversibility test at the screening visit,
             defined as ΔFEV1 ≥ 12% and ≥ 200 mL over baseline, 30 minutes after 400 μg salbutamol
             pMDI

          -  Patients free of long-acting beta2-agonists (LABAs) treatment for at least 2 weeks
             before the screening visit.

          -  Patients free of short-acting beta2-agonists (SABAs) treatment for at least 6 hours
             before the screening visit.

          -  Non-smokers or ex-smokers

        Exclusion Criteria:

          -  Pregnant or lactating women or all women physiologically capable of becoming pregnant
             UNLESS they are menopausal or are using effective and acceptable methods of
             contraception.

          -  Significant seasonal variation in asthma or asthma occurring only during episodic
             exposure to an allergen or a chemical sensitizer.

          -  History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma
             exacerbation in Intensive Care Unit) within 1 year before screening.

          -  Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks
             preceding the screening visit.

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency.

          -  Diagnosis of restrictive lung disease.

          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12
             weeks for parenteral depot corticosteroids) before screening visit.

          -  Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled
             corticosteroids.

          -  Allergy, sensitivity or intolerance to study drugs or excipients.

          -  Significant medical history of and/or treatments for cardiac, renal, neurological,
             hepatic, endocrine diseases, or any laboratory abnormality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Singh, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medecines Evaluation Unit - Southmoor Road - M23 9QZ Manchester - UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pr DS SINGH</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004842-10</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <name_title>Pr SD Singh</name_title>
    <organization>Medecines Evaluation Unit - Southmoor Road - M23 9QZ Manchester - United Kingdom</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

